These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 11442659)

  • 41. Rotational 3D-conformal radiation therapy (conformation therapy) combined with hormone therapy for the treatment of stage B2/C prostate cancer in Japanese men.
    Karasawa K; Kaizu T; Niibe Y; Igaki H; Shinohara M; Tanaka Y; Matsuda T
    Int J Radiat Oncol Biol Phys; 2003 May; 56(1):208-12. PubMed ID: 12694840
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Diethylstilboestrol versus bicalutamide in hormone refractory prostate carcinoma: a prospective randomized trial.
    Manikandan R; Srirangam SJ; Pearson E; Brown SC; O'Reilly P; Collins GN
    Urol Int; 2005; 75(3):217-21. PubMed ID: 16215308
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Neuroendocrine differentiation in adenocarcinoma of the prostate during hormonal treatment : a case report].
    Segawa N; Inamoto T; Ibuki N; Mizutani Y; Azuma H; Tsuji M; Katsuoka Y
    Hinyokika Kiyo; 2010 Jan; 56(1):49-54. PubMed ID: 20104011
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical features of patients who present with metastatic prostate carcinoma and serum prostate-specific antigen (PSA) levels < 10 ng/mL: the "PSA negative" patients.
    Birtle AJ; Freeman A; Masters JR; Payne HA; Harland SJ;
    Cancer; 2003 Dec; 98(11):2362-7. PubMed ID: 14635070
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prostate-specific antigen half-life and pretreatment prostate-specific antigen: crucial predictors for prostate-specific antigen trend in delayed-combined androgen blockade therapy.
    Soga N; Onishi T; Arima K; Sugimura Y
    Int J Urol; 2007 Mar; 14(3):192-6; discussion 197. PubMed ID: 17430253
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Does hormonal manipulation in conjunction with permanent interstitial brachytherapy, with or without supplemental external beam irradiation, improve the biochemical outcome for men with intermediate or high-risk prostate cancer?
    Merrick GS; Butler WM; Galbreath RW; Lief JH; Adamovich E
    BJU Int; 2003 Jan; 91(1):23-9. PubMed ID: 12614244
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prostate specific antigen findings and biopsy results following interactive ultrasound guided transperineal brachytherapy for early stage prostate carcinoma.
    Stock RG; Stone NN; DeWyngaert JK; Lavagnini P; Unger PD
    Cancer; 1996 Jun; 77(11):2386-92. PubMed ID: 8635111
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Combined hormonal and radiation therapy for lymph node-positive prostate cancer.
    Whittington R; Malkowicz B; Barnes MM; Broderick GA; Van Arsdalen K; Dougherty MJ; Wein AJ
    Urology; 1995 Aug; 46(2):213-9. PubMed ID: 7542824
    [TBL] [Abstract][Full Text] [Related]  

  • 49. An assessment of the usefulness of serum prostate-specific antigen level and cancer volume in biopsy specimens to predict the extent of prostate cancer.
    Gohji K; Nomi M; Kizaki T; Morisue K; Okamoto M; Takenaka A; Fujii A
    Br J Urol; 1997 Apr; 79(4):602-7. PubMed ID: 9126092
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Postneoadjuvant hormone PSA levels and prognosis in locally advanced prostate cancer.
    Velasco J; Tekyi-Mensah S; Bolton S; Forman JD
    Urology; 1999 Aug; 54(2):325-8. PubMed ID: 10443733
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Serum alkaline phosphatase flare in prostate cancer accompanied by bone metastases and treated with hormonal therapy. TEKK Study Group].
    Taue R; Kanayama H; Kagawa S
    Hinyokika Kiyo; 1999 Oct; 45(10):681-5. PubMed ID: 10586358
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Seven-month prostate-specific antigen (PSA) is prognostic in patients with prostate cancer initially diagnosed with distant metastases.
    Nieder C; Haukland E; Pawinski A; Norum J
    Med Oncol; 2018 Mar; 35(4):46. PubMed ID: 29508104
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Can initial prostate specific antigen determinations eliminate the need for bone scans in patients with newly diagnosed prostate carcinoma? A multicenter retrospective study in Japan.
    Kosuda S; Yoshimura I; Aizawa T; Koizumi K; Akakura K; Kuyama J; Ichihara K; Yonese J; Koizumi M; Nakashima J; Fujii H
    Cancer; 2002 Feb; 94(4):964-72. PubMed ID: 11920464
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effects of flutamide as a second-line agent for maximum androgen blockade of hormone refractory prostate cancer.
    Nishimura K; Arichi N; Tokugawa S; Yoshioka I; Kishikawa H; Ichikawa Y
    Int J Urol; 2007 Mar; 14(3):264-7. PubMed ID: 17430272
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Serum prostate-specific antigen as a predictor of staging abdominal/pelvic computed tomography in newly diagnosed prostate cancer.
    Huncharek M; Muscat J
    Abdom Imaging; 1996; 21(4):364-7. PubMed ID: 8661585
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Prognostic significance of prostate-specific antigen in defining indications for initial prostate biopsy].
    Popov SV; Guseinov RG; Skryabin ON; Orlov IN; Martov AG
    Urologiia; 2018 Jul; (3):92-97. PubMed ID: 30035426
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Correlation of prostate-specific antigen before prostate cancer detection and clinicopathologic features: evaluation of mass screening populations.
    Ito K; Kubota Y; Suzuki K; Shimizu N; Fukabori Y; Kurokawa K; Imai K; Yamanaka H
    Urology; 2000 May; 55(5):705-9. PubMed ID: 10792085
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Treatment of localized prostate cancer with intermittent triple androgen blockade: preliminary results in 110 consecutive patients.
    Leibowitz RL; Tucker SJ
    Oncologist; 2001; 6(2):177-82. PubMed ID: 11306729
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Hormonal therapy for patients with advanced adenocarcinoma of the prostate: is there a role for discontinuing treatment after prolonged androgen suppression?
    Pedraza R; Kwart AM
    Urology; 2003 Apr; 61(4):770-3. PubMed ID: 12670563
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Characterization of patients with androgen-independent prostatic carcinoma whose serum prostate specific antigen decreased following flutamide withdrawal.
    Herrada J; Dieringer P; Logothetis CJ
    J Urol; 1996 Feb; 155(2):620-3. PubMed ID: 8558675
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.